Identification of pY654-β-catenin as a critical co-factor in hypoxia-inducible factor-1α signaling and tumor responses to hypoxia

Oncogene

Volumn 32, Issue 42, 2013, Pages 5048-5057

  Xi, Y ^a   Wei, Y ^a   Sennino, B ^b   Ulsamer, A ^a   Kwan, I ^a   Brumwell, A N ^a   Tan, K ^a   Aghi, M K ^a   McDonald, D M ^b   Jablons, D M ^a   Chapman, H A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epithelial; Hypoxia; Signaling; Transcription; Tumor

Indexed keywords

ACETYLCYSTEINE; BETA CATENIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PY654 BETA CATENIN; REACTIVE OXYGEN METABOLITE; SMAD2 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HYPOXIA; LUNG ADENOCARCINOMA; ONCOGENE SRC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ADENOMA; ANIMALS; ANTIBODIES, NEUTRALIZING; BETA CATENIN; CELL HYPOXIA; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; NEUROENDOCRINE TUMORS; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SRC-FAMILY KINASES; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 84886100356     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.530     Document Type: Article

References (45)

1. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
2. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939. (Pubitemid 38798858)
3. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
4. Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of disease: epithelialmesenchymal transition-does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol 2008; 5: 280-290. (Pubitemid 351594144)
5. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010; 16: 5928-5935.
6. Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ. Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable nonsmall cell lung cancer. Thorax 2009; 64: 1082-1089.
7. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009; 107: 1053-1062.
8. De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 2011; 8: 393-404.
9. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
10. Klimova T, Chandel NS. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ 2008; 15: 660-666. (Pubitemid 351405069)
11. Cannito S, Novo E, Compagnone A, Valfre di Bonzo L, Busletta C, Zamara E et al. Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis 2008; 29: 2267-2278.
12. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH et al. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 2006; 66: 2725-2731.
13. Luo D, Wang J, Li J, Post M. Mouse snail is a target gene for HIF. Mol Cancer Res 2011; 9: 234-245.
14. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008; 10: 295-305.
15. Kaluz S, Kaluzova M, Stanbridge EJ. Regulation of gene expression by hypoxia: integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. Clin Chim Acta 2008; 395: 6-13.
16. Kaidi A, Williams AC, Paraskeva C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007; 9: 210-217. (Pubitemid 46420864)
17. Stemmer V, de Craene B, Berx G, Behrens J. Snail promotes Wnt target gene expression and interacts with beta-catenin. Oncogene 2008; 27: 5075-5080.
18. Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH et al. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol 2006; 8: 1398-1406. (Pubitemid 44835115)
19. Morin PJ. beta-catenin signaling and cancer. Bioessays 1999; 21: 1021-1030.
20. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999; 9: 15-21.
21. Roura S, Miravet S, Piedra J, Garcia de Herreros A, Dunach M. Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. J Biol Chem 1999; 274: 36734-36740.
22. Kim KK, Wei Y, Szekeres C, Kugler MC, Wolters PJ, Hill ML et al. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest 2009; 119: 213-224.
23. Kim Y, Kugler MC, Wei Y, Kim KK, Li X, Brumwell AN et al. Integrin alpha3beta1-dependent beta-catenin phosphorylation links epithelial Smad signaling to cell contacts. J Cell Biol 2009; 184: 309-322.
24. Ulsamer A, Wei Y, Kim KK, Tan K, Wheeler S, Xi Y et al. Axin pathway activity regulates in vivo pY654-beta-catenin accumulation and pulmonary fibrosis. J Biol Chem 2012; 287: 5164-5172.
25. Lilien J, Balsamo J. The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. Curr Opin Cell Biol 2005; 17: 459-465. (Pubitemid 41267159)
26. Zeng G, Apte U, Micsenyi A, Bell A, Monga SP. Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions. Exp Cell Res 2006; 312: 3620-3630. (Pubitemid 44470779)
27. Karni R, Dor Y, Keshet E, Meyuhas O, Levitzki A. Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1alpha expression under normoxia. J Biol Chem 2002; 277: 42919-42925. (Pubitemid 35285669)
28. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxiainducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 1997; 57: 5328-5335. (Pubitemid 27516371)
29. Pham NA, Magalhaes JM, Do T, Schwock J, Dhani N, Cao PJ et al. Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models. Int J Cancer 2009; 124: 280-286.
30. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347-361. (Pubitemid 38340304)
31. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-1113.
32. Zhou G, Dada LA, Wu M, Kelly A, Trejo H, Zhou Q et al. Hypoxia-induced alveolar epithelial-mesenchymal transition requires mitochondrial ROS and hypoxia-inducible factor 1. Am J Physiol Lung Cell Mol Physiol 2009; 297: L1120-L1130.
33. Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y et al. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 2010; 70: 2224-2234.
34. Lluis JM, Buricchi F, Chiarugi P, Morales A, Fernandez-Checa JC. Dual role of mitochondrial reactive oxygen species in hypoxia signaling: activation of nuclear factor-{kappa}B via c-SRC and oxidant-dependent cell death. Cancer Res 2007; 67: 7368-7377. (Pubitemid 47206567)
35. Setsukinai K, Urano Y, Kakinuma K, Majima HJ, Nagano T. Development of novel fluorescence probes that can reliably detect reactive oxygen species and distinguish specific species. J Biol Chem 2003; 278: 3170-3175. (Pubitemid 36801227)
36. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309. (Pubitemid 41443415)
37. Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012; 2: 270-287.
38. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 2008; 105: 4283-4288. (Pubitemid 351754372)
39. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA et al. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest 2009; 119: 2160-2170.
40. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012; 22: 21-35.
41. Lou YW, Chen YY, Hsu SF, Chen RK, Lee CL, Khoo KH et al. Redox regulation of the protein tyrosine phosphatase PTP1B in cancer cells. FEBS J 2008; 275: 69-88.
42. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011; 480: 118-122.
43. Grepin R, Pages G. Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J Oncol 2010; 2010: 835680.
44. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 2011; 108: 3749-3754.
45. Mao W, Irby R, Coppola D, Fu L, Wloch M, Turner J et al. Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 1997; 15: 3083-3090. (Pubitemid 28043487)